Hepatic Hippo signaling inhibits development of hepatocellular carcinoma
Primary liver cancer is one of the most common cancer worldwide. Hepatocellular carcinoma (HCC) in particular, is the second leading cause of cancer deaths in the world. The Hippo signaling pathway has emerged as a major oncosuppressive pathway that plays critical roles inhibiting hepatocyte prolife...
Main Authors: | Yuchen Liu, Xiaohui Wang, Yingzi Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2020-10-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2020-0178.pdf |
Similar Items
-
Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression
by: Du Jiamin, et al.
Published: (2022-09-01) -
Analysis of the role of the Hippo pathway in cancer
by: Yanyan Han
Published: (2019-04-01) -
Clinical and biological implications of Hippo pathway dysregulation in sarcomas
by: Kyriazoglou Anastasios, et al.
Published: (2019-07-01) -
Hippo Signaling in the Liver – A Long and Ever-Expanding Story
by: Saumya Manmadhan, et al.
Published: (2019-03-01) -
Hippo signaling impairs alveolar epithelial regeneration in pulmonary fibrosis
by: Rachel Warren, et al.
Published: (2023-05-01)